23 results about "Antifolate" patented technology

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Antibody constructs that bind human folate receptor alpha (FRα or FOLR1) and antibody-drug conjugates (ADCs) comprising an anti-FRα antibody construct conjugated to a drug, such as a cytotoxin or an immune modulator, and their use as therapeutics or diagnostics, for example, in the treatment or diagnosis of cancer.

The present invention describes a chimeric antigen receptor (CAR) specific for FOLR1, a vector encoding the FOLR1CAR, a recombinant host cell (CAR-T or CAR-NK) comprising the FOLR1CAR, and a method of using the CAR-T or CAR-NK to treat a disease associated with the expression of FOLR1. The present invention also describes a humanized anti-FOLR1 monoclonal antibody and an antigen-binding fragment thereof.

Disclosed is an antibody that specifically recognizes and binds to folate receptor α, also referred to as anti-folate receptor a antibody or anti-FRα antibody. Also disclosed is an antibody-drug conjugate of the anti-FRα antibody. Disclosed are uses of the anti-FRα antibody and the antibody-drug conjugate in the treatment of diseases related to FRα expression.

The disclosure relates generally to gamma polyglutamated Antifolate, formulations containing liposomes filled with gamma polyglutamated Antifolate, methods of making the gamma polyglutamated Antifolate and liposome containing formulations, and methods of using polyglutamated gamma polyglutamated Antifolate and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and an autoimmune disease such as rheumatoid arthritis).

The present disclosure relates generally to polyglutamic acid-modified antifolate agents, formulations containing liposomes filled with alpha or D-gamma polyglutamic acid-modified antifolate agents, methods of making polyglutamic acid-modified antifolate agents and liposomal-containing formulations, and methods of treating myeloproliferative disorders (e.g., cancer) and immune system disorders (e.g., autoimmune diseases, such as rheumatoid arthritis) using the polyglutamic acid-modified antifolate and the liposomal-containing formulations.

A method of inhibiting M2-like macrophages in a patient is provided comprising administering to a patient having ovarian cancer a therapeutically effective amount of a FRB-transported C1 inhibitor compound having selective efficacy to FRβ expressing tumor cells. The method includes wherein the FRB-transported C1 inhibitor compound is a substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitor compound having selective efficacy to FRβ expressing tumor cells. The present invention provides a method for targeting both the tumor and the tumor microenvironment with the FRB-transported C1 inhibitor compounds.

The name of the invention is polyglutamic acid-modified antifolic acid agents and uses thereof. The present disclosure relates generally to polyglutamic acid-modified antifolate agents, formulations containing liposomes filled with polyglutamic acid-modified antifolate agents, methods of making polyglutamic acid-modified antifolate agents and liposomal-containing formulations, and methods of making polyglutamic acid-modified antifolate agents and liposomal-containing formulations, and methods of treating myeloproliferative disorders (e.g., cancer) and immune system disorders (e.g., autoimmune diseases, such as rheumatoid arthritis) using the polyglutamic acid-modified antifolate and the liposomal-containing formulations.

Antibody-drug conjugates (ADCs) comprising antibody constructs that bind to human folate receptor alpha (FRα or FOLR1) and anti-FRα antibody constructs conjugated to drugs such as cytotoxins or immunomodulators, and their use as therapeutic or diagnostic agents, for example, in the treatment or diagnosis of cancer.

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with the polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using the polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to alpha polyglutamated Antifolates, formulations containing liposomes filled with alpha polyglutamated Antifolates, methods of making the alpha polyglutamated Antifolates and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated Antifolates and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Embodiments relate to a composition for inducing differentiation of stem cells into chondrocytes, a pharmaceutical composition for treatment of cartilage injury diseases, and a sustained-release dosage form for inducing differentiation of stem cells into chondrocytes, wherein the compositions and dosage form each comprise an antifolate. Using the composition for inducing differentiation of stem cells into chondrocytes according to one embodiment, it is possible to selectively induce stem cells to differentiate into chondrocytes without inducing differentiation into other cell types.

To provide gamma polyglutamated methotrexate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).SOLUTION: There is provided a liposomal composition comprising gamma polyglutamated methotrexate and a liposome encapsulating one or more non-polyglutamated, polyglutamatable antifolate compositions or non-polyglutamatable antifolates, wherein the liposome has a diameter of 50-150 nm.SELECTED DRAWING: None

The invention relates to the technical field of biological medicines, and particularly discloses application of a composition in preparation of anti-colorectal cancer medicines. The composition comprises an anti-folic acid drug and a pharmaceutically acceptable salt thereof, and an anti-creatine transport drug and a pharmaceutically acceptable salt thereof. Wherein the anti-folic acid medicine is used for inhibiting a folic acid-dependent nucleotide synthesis process and limiting DNA synthesis and replication of tumor cells, so that abnormal proliferation of the tumor cells is inhibited; the anti-creatine transport drug is used for inhibiting creatine uptake mediated by creatine transporter, reducing the level of phosphocreatine in cells and further weakening the energy buffering capacity and stress recovery capacity of tumor cells. According to the composition provided by the invention, two key metabolic pathways of nucleotide synthesis and energy homeostasis maintenance in colorectal cancer cells can be intervened at the same time, and dual inhibition and synergistic intervention are formed on the metabolism level, so that the inhibition effect on tumor cell proliferation and survival is enhanced; and the possibility of drug resistance of tumor cells to a single therapy through metabolic reprogramming can be reduced.

The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combination with other therapeutic agents.

The present disclosure relates to antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.

The invention provides an antibody drug conjugate targeting folate receptor alpha, and also discloses application of the antibody drug conjugate in preparation of drugs for treating folate receptor alpha-related tumors. The antibody drug conjugate provided by the invention combines the targeting property of the anti-folate receptor alpha antibody to folate receptor alpha expression cells, the strong endocytosis effect of a target spot and the toxic effect of a small molecule chemical drug, so that an excellent tumor killing effect is achieved.

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to alpha polyglutamated Antifolates, formulations containing liposomes filled with alpha polyglutamated Antifolates, methods of making the alpha polyglutamated Antifolates and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated Antifolates and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).